These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15784656)

  • 1. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
    Jacobson PB; von Geldern TW; Ohman L; Osterland M; Wang J; Zinker B; Wilcox D; Nguyen PT; Mika A; Fung S; Fey T; Goos-Nilsson A; Grynfarb M; Barkhem T; Marsh K; Beno DW; Nga-Nguyen B; Kym PR; Link JT; Tu N; Edgerton DS; Cherrington A; Efendic S; Lane BC; Opgenorth TJ
    J Pharmacol Exp Ther; 2005 Jul; 314(1):191-200. PubMed ID: 15784656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance.
    Zinker B; Mika A; Nguyen P; Wilcox D; Ohman L; von Geldern TW; Opgenorth T; Jacobson P
    Metabolism; 2007 Mar; 56(3):380-7. PubMed ID: 17292727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.
    Link JT; Sorensen B; Patel J; Grynfarb M; Goos-Nilsson A; Wang J; Fung S; Wilcox D; Zinker B; Nguyen P; Hickman B; Schmidt JM; Swanson S; Tian Z; Reisch TJ; Rotert G; Du J; Lane B; von Geldern TW; Jacobson PB
    J Med Chem; 2005 Aug; 48(16):5295-304. PubMed ID: 16078847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production.
    Edgerton DS; Jacobson PB; Opgenorth TJ; Zinker B; Beno D; von Geldern T; Ohman L; Scott M; Neal D; Cherrington AD
    Metabolism; 2006 Sep; 55(9):1255-62. PubMed ID: 16919547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
    Loffler M; Bilban M; Reimers M; Waldhäusl W; Stulnig TM
    J Pharmacol Exp Ther; 2006 Feb; 316(2):797-804. PubMed ID: 16260581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents.
    Home PD; Pacini G
    Diabetes Obes Metab; 2008 Sep; 10(9):699-718. PubMed ID: 17825080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy].
    Meyer G; Badenhoop K
    Med Klin (Munich); 2003 Apr; 98(5):266-70. PubMed ID: 12721671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
    Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression of mineralocorticoid and glucocorticoid receptors in the limbic system is related to type-2 like diabetes in leptin-resistant rats.
    Jöhren O; Dendorfer A; Dominiak P; Raasch W
    Brain Res; 2007 Dec; 1184():160-7. PubMed ID: 17945204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.
    Liang Y; Osborne MC; Monia BP; Bhanot S; Watts LM; She P; DeCarlo SO; Chen X; Demarest K
    Metabolism; 2005 Jul; 54(7):848-55. PubMed ID: 15988691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemic effect of hot-water extract of adzuki (Vigna angularis) in spontaneously diabetic KK-A(y) mice.
    Itoh T; Kobayashi M; Horio F; Furuichi Y
    Nutrition; 2009 Feb; 25(2):134-41. PubMed ID: 18929464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
    Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the liver on post-prandial glycaemia--emphasis on hepatic glucose uptake.
    Kawamori R
    Int J Clin Pract Suppl; 2000 Sep; (112):19-22. PubMed ID: 11064947
    [No Abstract]   [Full Text] [Related]  

  • 17. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
    Zuo YQ; Liu WP; Niu YF; Tian CF; Xie MJ; Chen XZ; Li L
    J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
    Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats.
    Park S; Hong SM; Ahn IS
    Metabolism; 2010 Jan; 59(1):123-33. PubMed ID: 19766272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.